Tag: early stage

ROAD TOWN, British Virgin Islands, Aug. 11, 2025 (GLOBE NEWSWIRE) -- LYNO AI is enjoying unprecedented interest with early adopters and whales rushing to participate in the soon to be over presale. The Early Bird presale has inspired high levels of investor confidence as over 259,000 tokens have been sold in a very short period of time.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs)

London, United Kingdom, Aug. 01, 2025 (GLOBE NEWSWIRE) -- MGPD Finance Limited, doing business as HashJ, today announced the official release of a new short-term participation contract focused on Bitcoin (BTC), designed for users navigating a market at a technical crossroads. The launch follows a period of directional indecision in the BTC market, as traders assess whether recent price action marks a consolidation phase or the early stage of a sustained move.

TORONTO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK / OTCQX:IDKFF) a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, is pleased to announce that it has closed its previously announced private placement financing (the “Private Placement”) pursuant to which it has issued an aggregate of 11,600,000 units (“Units”) of the Company in exchange for total gross proceeds of $696,000, or $0.06 per Unit.

With over $4 billion in net assets, the Global X Uranium ETF is the world’s preeminent ETF providing investors broad exposure to companies involved in uranium mining and the production of nuclear components

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI^®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.

The Oak Brook Facility will support up to the initial 60 nuclear engineers, researchers and support staff to work in collaboration with The University of Illinois Urbana-Champaign on NANO Nuclear’s lead microreactor project

Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this November